{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:31:43Z","timestamp":1780468303206,"version":"3.54.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":947,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation and plays a critical role in the assessment and prognosis in patients with heart failure. The EMPA-HEART CardioLink-6 trial demonstrated that patients with type 2 diabetes (T2D) and coronary artery disease (CAD) treated with a sodium\u2013glucose transport protein 2 inhibitor for 6 months experienced regression in left ventricular mass. Given this, we evaluated the relationship of baseline NLR and cardiac reverse remodelling in the entire cohort of this trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A total of 97 individuals were randomized to receive empagliflozin (10 mg\/day) or placebo for 6 months. The primary outcome of the trial was change in left ventricular mass indexed to body surface area (LVMi) from baseline to 6 months as measured by cardiac magnetic resonance imaging. In our analysis, the cohort was stratified above and below an NLR level of 2. To assess the treatment effect on the 6 month change in NLR, we used a linear model adjusting for baseline differences in NLR [analysis of covariance (ANCOVA)] that included an interaction term between the baseline NLR and treatment. To assess the treatment effect on the 6 month change in LVMi in each of the subgroups divided by baseline NLR, we used an ANCOVA adjusting for baseline differences in LVMi that included an interaction term between the subgroups and treatment. The results of the regression models were summarized as adjusted differences with two-sided 95% confidence intervals (CIs). Patients who exhibited an elevated baseline NLR demonstrated higher LVMi and left ventricular end-diastolic volume indexed to body surface area than those with a lower NLR. In patients with an NLR &amp;lt; 2 and NLR \u2265 2, the adjusted difference in LVMi between the empagliflozin- and placebo-treated patients was \u22122.98 g\/m2 (95% CI: \u22126.18 to 0.22 g\/m2) (P value = 0.067) and \u22124.43 g\/m2 (95% CI: \u22128.50 to \u22121.11 g\/m2), respectively (Pinteraction = 0.60).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Empagliflozin treatment is associated with consistent reductions in LVMi in patients with T2D and CAD independent of baseline NLR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14351","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T01:47:44Z","timestamp":1681177664000},"page":"2127-2133","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Baseline Neutrophil-to-Lymphocyte Ratio and Efficacy of SGLT2 Inhibition with Empagliflozin on Cardiac Remodelling"],"prefix":"10.1093","volume":"10","author":[{"given":"Raj","family":"Verma","sequence":"first","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"School of Medicine, Royal College of Surgeons in Ireland , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Moroney","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"School of Medicine, Royal College of Surgeons in Ireland , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Emory University School of Medicine , Atlanta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril David","family":"Mazer","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Anesthesiology and Pain Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Physiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Connelly","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Physiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Cardiology, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Cardiology, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Quan","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee","family":"Teoh","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Endocrinology and Metabolism, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Pharmacology and Toxicology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Puar","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Pharmacology and Toxicology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Faculty of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"2026012114104990500_ehf214351-bib-0001","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114104990500_ehf214351-bib-0002","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114104990500_ehf214351-bib-0003","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114104990500_ehf214351-bib-0004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2026012114104990500_ehf214351-bib-0005","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114104990500_ehf214351-bib-0006","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"2026012114104990500_ehf214351-bib-0007","article-title":"Neutrophil to lymphocyte ratio as a predictor of left ventricular hypertrophy in patients with newly diagnosed hypertension","volume":"5","author":"Af\u015fin","year":"2019","journal-title":"J Hypertens Manag"},{"key":"2026012114104990500_ehf214351-bib-0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024091","article-title":"Neutrophil-to-lymphocyte ratios in patients undergoing aortic valve replacement: the PARTNER trials and registries","volume":"11","author":"Shahim","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026012114104990500_ehf214351-bib-0009","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil\u2013lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114104990500_ehf214351-bib-0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/jcm9020557","article-title":"Neutrophil-lymphocyte ratio in patients with acute heart failure predicts in-hospital and long-term mortality","volume":"9","author":"Cho","year":"2020","journal-title":"J Clin Med"},{"key":"2026012114104990500_ehf214351-bib-0011","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJM197406062902302","article-title":"The leukocyte count as a predictor of myocardial infarction","volume":"290","author":"Friedman","year":"1974","journal-title":"N Engl J Med"},{"key":"2026012114104990500_ehf214351-bib-0012","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jacc.2005.02.054","article-title":"Which white blood cell subtypes predict increased cardiovascular risk?","volume":"45","author":"Horne","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012114104990500_ehf214351-bib-0013","first-page":"17","article-title":"Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update","volume":"40","author":"Madjid","year":"2013","journal-title":"Tex Heart Inst J"},{"key":"2026012114104990500_ehf214351-bib-0014","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2004.07.056","article-title":"Leukocyte count and coronary heart disease: implications for risk assessment","volume":"44","author":"Madjid","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026012114104990500_ehf214351-bib-0015","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2703518","article-title":"Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis","volume":"2018","author":"Angkananard","year":"2018","journal-title":"Biomed Res Int"},{"key":"2026012114104990500_ehf214351-bib-0016","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012813","article-title":"Association of lymphocyte to monocyte ratio with severity of coronary artery disease","volume":"97","author":"Gong","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026012114104990500_ehf214351-bib-0017","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.amjcard.2010.03.062","article-title":"Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction","volume":"106","author":"Azab","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026012114104990500_ehf214351-bib-0018","first-page":"296","article-title":"The neutrophil to lymphocyte ratio in heart failure: a comprehensive review","volume":"57","author":"Delcea","year":"2019","journal-title":"Rom J Intern Med"},{"key":"2026012114104990500_ehf214351-bib-0019","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.576005","article-title":"Neutrophil to lymphocyte ratio is increased and associated with left ventricular diastolic function in newly diagnosed essential hypertension children","volume":"9","author":"Hou","year":"2021","journal-title":"Front Pediatr"},{"key":"2026012114104990500_ehf214351-bib-0020","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.2479","article-title":"Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6","volume":"42","author":"Verma","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114104990500_ehf214351-bib-0021","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.614757","article-title":"High neutrophil to lymphocyte ratio and its gene signatures correlate with diastolic dysfunction in heart failure with preserved ejection fraction","volume":"8","author":"Bai","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026012114104990500_ehf214351-bib-0022","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12902-020-00571-y","article-title":"Neutrophil: lymphocyte ratio is positively associated with subclinical diabetic cardiomyopathy","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"2026012114104990500_ehf214351-bib-0023","doi-asserted-by":"crossref","DOI":"10.1097\/01.hjh.0000752460.12125.91","article-title":"28. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a predictor for left ventricular hypertrophy (LVH) in patients with hypertension: a systematic review and meta-analyses","volume":"39","author":"Multazam","year":"2021","journal-title":"J Hypertens"},{"key":"2026012114104990500_ehf214351-bib-0024","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1536\/ihj.19-138","article-title":"NLR\u2014a simple indicator of inflammation for the diagnosis of left ventricular hypertrophy in patients with hypertension","volume":"61","author":"Yu","year":"2020","journal-title":"Int Heart J"},{"key":"2026012114104990500_ehf214351-bib-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/FC.2018.0001","article-title":"The role of neutrophil to lymphocyte ratio as a predictor of left ventricular diastolic dysfunction in chronic kidney disease patients","volume":"13","author":"Gromadzi\u0144ski","year":"2018","journal-title":"Folia Cardiol"},{"key":"2026012114104990500_ehf214351-bib-0026","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.repc.2016.09.014","article-title":"The importance of the neutrophil-to-lymphocyte ratio in patients with hypertrophic cardiomyopathy","volume":"36","author":"Ozyilmaz","year":"2017","journal-title":"Rev Port Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2127\/65017846\/eschf_10_3_2127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2127\/65017846\/eschf_10_3_2127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:12:00Z","timestamp":1769022720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/2127\/8304721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,4,10]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14351","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"2022-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}